2009 7-9

Recently CapitalBio Corporation, China’s leading developer of microarray diagnostic products and total analysis solutions announced its Deafness Gene Mutation Detection Array Kit products had received a certificate for diagnostic use from the China State Food and Drug Administration (SFDA).

“International symposium of Deafness and Genetic Medicine” was held jointly by CapitalBio Corporation and 301 Hospital in the main Surgery Building of 301 Hospital on 29^th and 30^th August, 2009.

In August 2009, two new products, namely CapitalBio M.Tuberculosis Drug Resistance Detection Array Kit and CapitalBio Mycobacterial Species Identification Array Kit developed by CapitalBio were accredited as “Beijing Independent Innovation Product” among fifth batch of innovation products. 

On wednesday 29 July, 2009, CapitalBio Corporation and VigeneTech Inc. have announced the launch of a fully integrated microarray solution platform.  CapitalBio Corp., a developer and marketer of diagnostic biochips and advanced microarray instrument systems, in collaboration with VigeneTech Inc., developers of novel image analysis, automation, and instrumentation software, now offer a platform that combines the superior performance and “one-click” automation of the MicroVigene™ image analysis suite with the long established performance of CapitalBio’s LuxScan™ microarray scanners.